Related references
Note: Only part of the references are listed.Safety, tolerability, and pharmacokinetics of BMS-986263/ND-L02-s0201, a novel targeted lipid nanoparticle delivering HSP47 siRNA, in healthy participants: A randomised, placebo-controlled, double-blind, phase 1 study
B. Soule et al.
JOURNAL OF HEPATOLOGY (2018)
Advanced siRNA Designs Further Improve In Vivo Performance of GaINAc-siRNA Conjugates
Donald J. Foster et al.
MOLECULAR THERAPY (2018)
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
D. Adams et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics
Aaron D. Springer et al.
NUCLEIC ACID THERAPEUTICS (2018)
Circular siRNAs for Reducing Off-Target Effects and Enhancing Long-Term Gene Silencing in Cells and Mice
Liangliang Zhang et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2018)
Tumor Microenvironment-Responsive Multistaged Nanoplatform for Systemic RNAi and Cancer Therapy
Xiaoding Xu et al.
NANO LETTERS (2017)
A drug-delivery strategy for overcoming drug resistance in breast cancer through targeting of oncofetal fibronectin
Phei Er Saw et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2017)
Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates
Jayaprakash K. Nair et al.
NUCLEIC ACIDS RESEARCH (2017)
Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement.
A. Cervantes et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Safety and Tolerability Study of an Intravenously Administered Small Interfering Ribonucleic Acid (siRNA) Post On-Pump Cardiothoracic Surgery in Patients at Risk of Acute Kidney Injury
Segav Demirjian et al.
KIDNEY INTERNATIONAL REPORTS (2017)
Drugging the 'undruggable' cancer targets
Chi V. Dang et al.
NATURE REVIEWS CANCER (2017)
Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers
Thomas Schluep et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Ultra-pH-Responsive and Tumor-Penetrating Nanoplatform for Targeted siRNA Delivery with Robust Anti-Cancer Efficacy
Xiaoding Xu et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Anti-tumor activity of a MYC-targeting dicer substrate siRNA in combination with BRD4/CDK7 inhibitors
Edmond Chipumuro et al.
CANCER RESEARCH (2016)
Lipid nanoparticles for targeted siRNA delivery - going from bench to bedside
Timofei S. Zatsepin et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2016)
Red-flag symptom clusters in transthyretin familial amyloid polyneuropathy
Isabel Conceicao et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2016)
Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial
Jake Dunning et al.
PLOS MEDICINE (2016)
Preclinical and clinical development of siRNA-based therapeutics
Gulnihal Ozcan et al.
ADVANCED DRUG DELIVERY REVIEWS (2015)
Evolving landscape in the management of transthyretin amyloidosis
Philip N. Hawkins et al.
ANNALS OF MEDICINE (2015)
Antibody-Mediated Delivery of Anti-KRAS-siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer
Sebastian Baeumer et al.
CLINICAL CANCER RESEARCH (2015)
Harnessing RNA Interference for Therapy The Silent Treatment
Judy Lieberman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Clinical experiences with systemically administered siRNA-based therapeutics in cancer
Jonathan E. Zuckerman et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Knocking down disease: a progress report on siRNA therapeutics
Anders Wittrup et al.
NATURE REVIEWS GENETICS (2015)
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients
Talia Golan et al.
ONCOTARGET (2015)
siRNA Versus miRNA as Therapeutics for Gene Silencing
Jenny K. W. Lam et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
Cationic cell-penetrating peptides as vehicles for siRNA delivery
Jagadish Beloor et al.
THERAPEUTIC DELIVERY (2015)
Multifunctional, self-assembling anionic peptide-lipid nanocomplexes for targeted siRNA delivery
Aristides D. Tagalakis et al.
BIOMATERIALS (2014)
Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing
Jayaprakash K. Nair et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
Kevin Fitzgerald et al.
LANCET (2014)
Adsorption and Release of siRNA from Porous Silica
Jeremy L. Steinbacher et al.
LANGMUIR (2014)
THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis
Teresa Coelho et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
Phase I First-in-Humans Trial of ALN-TTRsc, a Novel RNA Interference Therapeutic for the Treatment of Familial Amyloidotic Cardiomyopathy (FAC)
Tracy Zimmermann et al.
JOURNAL OF CARDIAC FAILURE (2013)
Delivery materials for siRNA therapeutics
Rosemary Kanasty et al.
NATURE MATERIALS (2013)
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
Teresa Coelho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Guideline of transthyretin-related hereditary amyloidosis for clinicians
Yukio Ando et al.
ORPHANET JOURNAL OF RARE DISEASES (2013)
First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
Josep Tabernero et al.
CANCER DISCOVERY (2013)
RNA-Based Therapeutics: Current Progress and Future Prospects
John C. Burnett et al.
CHEMISTRY & BIOLOGY (2012)
Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors
Dirk Strumberg et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2012)
The Transthyretin Amyloidoses: From Delineating the Molecular Mechanism of Aggregation Linked to Pathology to a Regulatory-Agency-Approved Drug
Steven M. Johnson et al.
JOURNAL OF MOLECULAR BIOLOGY (2012)
siRNA-optimized Modifications for Enhanced In Vivo Activity
Denise M. Kenski et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2012)
RNA Interference Therapy in Lung Transplant Patients Infected with Respiratory Syncytial Virus
Martin R. Zamora et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Current progress of siRNA/shRNA therapeutics in clinical trials
John C. Burnett et al.
BIOTECHNOLOGY JOURNAL (2011)
Preclinical characterization of TKM-080301, a lipid nanoparticle formulation of a small interfering RNA directed against polo-like kinase
Sean C. Semple et al.
CANCER RESEARCH (2011)
Nanocarriers: a tool to overcome biological barriers in siRNA delivery
Avnesh Kumari et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Promise and Challenge of RNA Interference-Based Therapy for Cancer
Fabio Petrocca et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids
Marija Tadin-Strapps et al.
JOURNAL OF LIPID RESEARCH (2011)
The ups and downs of Myc biology
Laura Soucek et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2010)
Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib
Michael Koldehoff et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
First-in-human Mutation-targeted siRNA Phase Ib Trial of an Inherited Skin Disorder
Sancy A. Leachman et al.
MOLECULAR THERAPY (2010)
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Mark E. Davis et al.
NATURE (2010)
Delivering nanomedicine to solid tumors
Rakesh K. Jain et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application
Aimee L. Jackson et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus
John DeVincenzo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
RNA Interference-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral Strategy
Rene Alvarez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
siRNA Conjugate Delivery Systems
Ji Hoon Jeong et al.
BIOCONJUGATE CHEMISTRY (2009)
The First Targeted Delivery of siRNA in Humans via a Self-Assembling, Cyclodextrin Polymer-Based Nanoparticle: From Concept to Clinic
Mark E. Davis
MOLECULAR PHARMACEUTICS (2009)
Layer-by-Layer Assembled Gold Nanoparticles for siRNA Delivery
Asmaa Elbakry et al.
NANO LETTERS (2009)
Knocking down barriers: advances in siRNA delivery
Kathryn A. Whitehead et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
RNA major groove modifications improve siRNA stability and biological activity
Montserrat Terrazas et al.
NUCLEIC ACIDS RESEARCH (2009)
siRNA and Innate Immunity
Marjorie Robbins et al.
OLIGONUCLEOTIDES (2009)
Comparative Study of Intravitreal Bevacizumab (Avastin) versus Ranibizumab (Lucentis) in the Treatment of Neovascular Age-Related Macular Degeneration
Gennady Landa et al.
OPHTHALMOLOGICA (2009)
Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth
Won Gil Cho et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
COMBINATION THERAPY USING THE SMALL INTERFERING RNA BEVASIRANIB
Lawrence Singerman
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2009)
COMPARISON OF INTRAVITREAL BEVACIZUMAB FOLLOWED BY RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Kimberly E. Stepien et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2009)
Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
Manuela Aleku et al.
CANCER RESEARCH (2008)
Misinterpreting the Therapeutic Effects of Small Interfering RNA Caused by Immune Stimulation
Marjorie Robbins et al.
HUMAN GENE THERAPY (2008)
Delivery vehicles for small interfering RNA in vivo
Antonin R. De Fougerolles
HUMAN GENE THERAPY (2008)
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3
Mark E. Kleinman et al.
NATURE (2008)
Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone
Yasushi Sato et al.
NATURE BIOTECHNOLOGY (2008)
Nonviral delivery of synthetic siRNAs in vivo
Saghir Akhtar et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Interfering with disease: a progress report on siRNA-based therapeutics
Antonin de Fougerolles et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
RNAi therapeutics: a potential new class of pharmaceutical drugs
David Bumcrot et al.
NATURE CHEMICAL BIOLOGY (2006)
A brief history of RNAi: the silence of the genes
George L. Sen et al.
FASEB JOURNAL (2006)
Widespread siRNA off-target'' transcript silencing mediated by seed region sequence complementarity
Aimee L. Jackson et al.
RNA (2006)
RNAi-mediated gene silencing in non-human primates
TS Zimmermann et al.
NATURE (2006)
Chemical modification of siRNAs to improve serum stability without loss of efficacy
S Choung et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Progress towards in vivo use of siRNAs
MA Behlke
MOLECULAR THERAPY (2006)
3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets
A Birmingham et al.
NATURE METHODS (2006)
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
DV Morrissey et al.
NATURE BIOTECHNOLOGY (2005)
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery
CN Landen et al.
CANCER RESEARCH (2005)
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
EW Song et al.
NATURE BIOTECHNOLOGY (2005)
Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication
DV Morrissey et al.
HEPATOLOGY (2005)
Induction of inflammatory cytokines and interferon responses by double-stranded and single-stranded siRNAs is sequence-dependent and requires endosomal localization
M Sioud
JOURNAL OF MOLECULAR BIOLOGY (2005)
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
AD Judge et al.
NATURE BIOTECHNOLOGY (2005)
A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA
LB Jeffs et al.
PHARMACEUTICAL RESEARCH (2005)
Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7
V Hornung et al.
NATURE MEDICINE (2005)
The silent revolution: RNA interference as basic biology, research tool, and therapeutic
DM Dykxhoorn et al.
ANNUAL REVIEW OF MEDICINE (2005)
siRNA therapeutics: Big potential from small RNAs
RCC Ryther et al.
GENE THERAPY (2005)
Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo
YH Wang et al.
BREAST CANCER RESEARCH (2005)
In vivo activity of nuclease-resistant siRNAs
JM Layzer et al.
RNA (2004)
Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3
K Karikó et al.
JOURNAL OF IMMUNOLOGY (2004)
Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury
P Hamar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Activation of the interferon system by short-interfering RNAs
CA Sledz et al.
NATURE CELL BIOLOGY (2003)
Interfering with disease: opportunities and roadblocks to harnessing RNA interference
J Lieberman et al.
TRENDS IN MOLECULAR MEDICINE (2003)
Expression profiling reveals off-target gene regulation by RNAi
AL Jackson et al.
NATURE BIOTECHNOLOGY (2003)
RNA interference targeting Fas protects mice from fulminant hepatitis
EW Song et al.
NATURE MEDICINE (2003)
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
SM Elbashir et al.
NATURE (2001)
An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells
SM Hammond et al.
NATURE (2000)
Share Paper
